Abstract

Objective

Investigate the longitudinal association of use and time of use of proton pump inhibitors (PPI) with incidence of chronic kidney disease (CKD) and kidney function change.

Methods

Prospective study with 13,909 participants from baseline (2008–2010) and second wave (2012–2014) of the ELSA-Brasil (mean interval between visits = 3.9 years (1.7–6.0)). Participants answered about use and time use of the PPI in the two weeks prior the interview. Renal function was assessed by glomerular filtration rate estimated by the Collaboration Equation for the Epidemiology of Chronic Kidney Disease. Values below 60ml/min/1.73 m² in wave 2 were considered incident CKD. Associations between PPI use and time of use at baseline and incident CKD and decline in renal function were estimated, respectively, by logistic regression and linear models with mixed effects, after adjusting for confounders.

Results

After adjustments, PPI users for more than six months had an increased risk of CKD compared to non-users. Compared to non-users, users PPIs for up to six months and above six months had greater decline in kidney function over time.

Conclusion

This cohort of adults and elderly, after a mean interval of 3.9 years, PPI use and initial duration were associated with kidney function change between visits.

Details

Title
Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort
Author
Andrêza Soares dos Santos; Teles de Menezes, Sara; Isabella Ribeiro Silva; William Neves Oliveira; Mariana Linhares Pereira; José Geraldo Mill; Barreto, Sandhi Maria; Roberta Carvalho Figueiredo
Pages
1-10
Section
Research
Publication year
2023
Publication date
2023
Publisher
BioMed Central
e-ISSN
14712369
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2877491417
Copyright
© 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.